Compare
PepGen Inc. vs Gossamer Bio, Inc. vs Eledon Pharmaceuticals, Inc. vs Corbus Pharmaceuticals Holdings, Inc.
| Latest fiscal year | PepGen Inc. PEPG | Gossamer Bio, Inc. GOSS | Eledon Pharmaceuticals, Inc. ELDN | Corbus Pharmaceuticals Holdings, Inc. CRBP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $48.47M | n/a | n/a |
| Revenue growth (YoY) | n/a | -57.7% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -352.2% | n/a | n/a |
| Net margin | n/a | -351.5% | n/a | n/a |
| Net income | -$89.66M | -$170.37M | -$45.62M | -$78.54M |
| EPS (Diluted) | -$2.12 | -$0.75 | -$0.52 | -$5.90 |
| Operating cash flow | -$81.64M | -$171.27M | -$62.34M | -$64.49M |
| Free cash flow | -$81.90M | -$171.34M | n/a | -$64.50M |
| Cash & equivalents | $60.51M | $37.73M | $22.81M | $28.49M |
| Total assets | $173.91M | $172.25M | $169.01M | $168.19M |
| Total liabilities | $26.46M | $295.01M | $32.23M | $20.69M |
| Shareholders' equity | $147.44M | -$122.76M | $81.08M | $147.50M |
| Return on year-end equity | -60.8% | n/a | -56.3% | -53.2% |
| Shares outstanding | 68.87M | 233.68M | 75.43M | 17.61M |
Revenue, most recent five fiscal years
| Fiscal year | PepGen Inc. | Gossamer Bio, Inc. | Eledon Pharmaceuticals, Inc. | Corbus Pharmaceuticals Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $48.47M Ended 2025-12-31 | $0 Ended 2016-12-31 | $0 Ended 2022-12-31 |
| 1 year earlier | n/a | $114.70M Ended 2024-12-31 | $0 Ended 2015-12-31 | $881.7K Ended 2021-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | n/a | $3.94M Ended 2020-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | n/a | $36.14M Ended 2019-12-31 |
| 4 years earlier | n/a | n/a | n/a | $4.82M Ended 2018-12-31 |